Key result
Elevated sCD40L is linked to vascular endothelial damage in lean and obese women with PCOS.
Why the study?
Soluble CD40 ligand is a transmembrane protein leading to endothelial damage and vascular disease, and this study aimed to detect changes in serum sCD40L levels in women with PCOS without obvious cardiac pathology.
Does polycystic ovary syndrome increase serum soluble CD40 ligand (sCD40L) levels in lean and obese women without obvious cardiac pathology compared to healthy controls?
Case-Control (n=60)
Does polycystic ovary syndrome increase serum soluble CD40 ligand (sCD40L) levels in lean and obese women without obvious cardiac pathology compared to healthy controls?
Elevated serum sCD40L in both lean and obese women with PCOS without overt heart disease suggests it may serve as an early biomarker of vascular endothelial damage in this population.
Soluble CD40 ligand and PCOSSoluble CD40 ligand (sCD40L) may be a predictive marker of vascular endothelial damage in lean and obese women with PCOS Abstract Aim: Soluble CD40 ligand (sCD40L) is a transmembrane protein that leads to endothelial damage and the emergence of vascular diseases.This study was designed to detect the change in serum sCD40L levels in women with PCOS without obvious cardiac pathology.Material and Methods: A total of 60 patients, including 40 PCOS patients without overt heart disease and 20 non-PCOS healthy controls, were included in the study.ECG and, if necessary, echocardiography were performed to investigate the presence of cardiac pathologies.The PCOS patients were divided into two subgroups according to their BMI values.Group 1: normal/lean PCOS (n=20), Group 2: overweight PCOS (n=20).Patients with a BMI of 18.5-24.9kg/m2 were considered normal or underweight.Those with a BMI of 25.0-29.9kg/m2 were considered obese.sCD40L levels in venous blood samples were measured with ELISA.Results: The serum sCD40L values of the obese PCOS group were higher than in both the lean PCOS and the control groups.Lean PCOS group had a higher serum sCD40L value than the control group.The serum LH value in the obese PCOS group was significantly higher than in the patients in both the lean PCOS and control groups.Serum testosterone levels of the participants in the lean and obese PCOS group were significantly higher than in the control group.The HOMA-IR value in the obese group was significantly higher than in both the lean PCOS and control groups.A positive and significant correlation was found between serum sCD40L, BMI and LH levels in both lean and obese PCOS groups.Similarly, a positive and significant correlation was found between serum testosterone, HOMA-IR and serum sCD40L values in both lean and obese PCOS groups.Discussion: The significant increase in sCD40L in both lean and obese PCOS patients without obvious cardiovascular disease suggests that it can be used as a marker of endothelial damage.
No takes yet. Share an insight, caveat, or question.
Kalı et al. (2023) conducted a case-control in Polycystic ovary syndrome (PCOS) without obvious cardiac pathology (n=60). Polycystic ovary syndrome (lean and obese/overweight subgroups) vs. Non-PCOS healthy controls was evaluated on Serum soluble CD40 ligand (sCD40L) levels measured by ELISA. Women with PCOS in both obese (n=20) and lean (n=20) subgroups had significantly higher serum sCD40L levels than healthy non-PCOS controls (n=20).
Synapse has enriched 5 related papers. Consider them for comparative context: